Development of Ploidy and Cell Proliferation in Serial Samples of Ascites from Patients with Ovarian Carcinoma

References

• Foulds L. Tumor progression. Cancer Res 1957; 17: 355–6
   PubMed Web of Science ®Google Scholar
• Nowell P. C. Mechanisms of tumor progression. Cancer Res 1986; 46: 2203–7
   PubMed Web of Science ®Google Scholar
• Sandberg A. A. The chromosomes in human cancer and leukaemia. ElseviedNorth-Holland Biomedical Press, New York, Amsterdam 1980
   Google Scholar
• Nowell P. C., Balban G. Karyotype progression and metastatis formation of human tumors. Biochemistry and molecular genetics of cancer metastatis, K. Lapis, L. Liotta, A. Rabson. Martinus Nijhoff, The Haugue 1986; 129–36
   Google Scholar
• Mackillop W. J., Trent J. M., Stewart S. S., Buick R. N. Tumor progression studied by analysis of cellular features of serial ascitic ovarian carcinoma tumors. Cancer Res 1983; 43: 874–8
   PubMed Web of Science ®Google Scholar
• Katayama K. P., Toews H. A. Chromosomes of metastatic ovarian carcinoma treated with progesterones and ankylating agents. Am J Obstet Gynaecol 1969; 104: 997–1003
   PubMed Web of Science ®Google Scholar
• Buick R. N., Pullano R., Trent J. M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985; 45: 3668–76
   PubMed Web of Science ®Google Scholar
• Tribukait B. Flowcytometry in assessing the clinical aggressiveness of genitourinary neoplasms. World J Urol 1987; 5: 108–22
   Web of Science ®Google Scholar
• Dolobeare F., Gratzner H. G., Pallavicini M. G., Gray J. Flowcy-tometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 1983; 80: 5573–7
   PubMed Web of Science ®Google Scholar
• Wilson G. D., McAlly N. J., Dunphy E., Karcher H., Hragner R. The labelling index of human and mouse tumors assessed by bromodeoxyuridine staining in vitro and in vivo and flow cytometry. Cytometry 1985; 6: 641–7
   PubMedGoogle Scholar
• Baisch H., Gohde W., Linden W. A. Analysis of PCP data to determine the fraction of cells in various phases of cell cycle. Radiation Environ Biophys 1975; 12: 31–9
   PubMed Web of Science ®Google Scholar
• Tribukait B. Clinical DNA flowcytometry. Med Oncol Tumor Pharmacother 1984; 1: 211–8
   PubMedGoogle Scholar
• Friedlander M. L., Hedley D. W., Tayler I. W., Russel P., Coates A. S., Tattersall M. H. N. Influence cellular DNA content on survival in advanced ovarian carcinoma. Cancer Res 1984; 44: 397400
   Web of Science ®Google Scholar
• Friedlander M. L., Taylor I. W., Russel P., Musgrove E. A., Hadley D. W., Tattersall M. H. N. Ploidy as a prognostic factor in ovarian cancer. Int J Gynecol Pathol 1983; 2: 55–63
   PubMed Web of Science ®Google Scholar
• Sahni K., Fibukait B., Einhorn N. Comparative study of proportion of S-phase cells in ascites and pleural effusions in ovarian carcinoma using antibromodeoxyuridine monoclonal antibody and DNA flow cytometry. Acta Oncol 1989; 28: 705–8
   PubMed Web of Science ®Google Scholar
• Skog S., Tribukait B. Analysis of cell flow and cell loss following x-irradiation using sequential investigation of the total number of the cells in the various parts of the cell cycle. Cell Tissue Kinet 1985; 18: 4274
   Google Scholar
• Curt G. A., Clendeninn N. J., Chabner B. A. Drug resistance in cancer. Cancer Treat Rep 1984; 68: 87–99
   PubMedGoogle Scholar
• Ozol R. F., Cowan K. New aspects of clinical drug resistance. The role of gene amplification and the reversal of resistance of drug refractory cancer. Important Adv Oncol 1986; 129–57
   PubMedGoogle Scholar
• Schimke R. T. Gene amplification, drug resistance, and cancer. Cancer Res 1984; 44: 173542
   Web of Science ®Google Scholar
• Busch H. Oncogenes and other new targets for cancer chemotherapy. (WHO), Carcino-genicity of alkylating agents, Cytostatic drugs I.A.R.C. scientific publication, D. Schmähl, J. M. Kaldor. International agency for cancer, Lyon 1986; 78: 309–20
   Google Scholar
• Hansson J., Tribukait B., Lewensohn R., Ringborg U. Flow cytofluorometric DNA analysis of metastases of human malignant melanomas. Anal Quant Cytol Histol 1982; 25: 99–104
   Google Scholar
• Kimby E., Mellsted H., Nilsson B., Tribukait B., Björkholm Holm G. S-phase lymphocytes in chronic lymphocytic leukemia (CLL) in relation to immunoglobulin isotypes on the leukemic clone and to the disease activity. Leukemia 1987; 1: 432–6
   PubMed Web of Science ®Google Scholar
• Tubiana M., Pejovic M. H., Chavadura N., Contesso G., Malaise E. P. The long-term index of the prognostic significance of the thymidine labelling index in the breast cancer. Int J Cancer 1984; 33: 441–5
   PubMed Web of Science ®Google Scholar